Qiagen (NYSE:QGEN) Given Buy Rating at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of Qiagen (NYSE:QGEN) in a report issued on Tuesday morning, Marketbeat Ratings reports. They currently have a $54.00 price objective on the stock, up from their prior price objective of $42.00.

A number of other brokerages also recently issued reports on QGEN. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Thursday, October 17th. Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and a consensus price target of $51.15.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $45.97 on Tuesday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $10.49 billion, a PE ratio of 117.87, a price-to-earnings-growth ratio of 3.37 and a beta of 0.35. The firm’s 50 day moving average price is $43.18 and its 200-day moving average price is $43.70. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44.

Institutional Investors Weigh In On Qiagen

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in shares of Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the last quarter. Blue Trust Inc. increased its stake in Qiagen by 21.0% in the 2nd quarter. Blue Trust Inc. now owns 7,891 shares of the company’s stock worth $339,000 after acquiring an additional 1,369 shares during the last quarter. Raymond James & Associates boosted its position in shares of Qiagen by 12.7% during the 2nd quarter. Raymond James & Associates now owns 542,453 shares of the company’s stock valued at $22,289,000 after acquiring an additional 61,008 shares during the last quarter. Mayfair Advisory Group LLC purchased a new position in shares of Qiagen in the second quarter valued at $268,000. Finally, Fifth Third Bancorp increased its position in Qiagen by 9.4% in the second quarter. Fifth Third Bancorp now owns 76,592 shares of the company’s stock worth $3,147,000 after purchasing an additional 6,573 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.